<DOC>
	<DOCNO>NCT01115751</DOCNO>
	<brief_summary>Study JWAA multicenter , nonrandomized , open-label , dose-escalation Phase 1 study oral LY2780301 patient advance solid tumor .</brief_summary>
	<brief_title>A Study Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>JWAA consist follow treatment phase part : Part A - Dose escalation phase use once-daily dosing schedule . Part B - Dose escalation phase use twice-daily dosing schedule . Part C - Dose expansion phase use maximum tolerate dose either Part A Part B .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Have histological cytological evidence diagnosis cancer advance and/or metastatic ( include NonHodgkin 's Lymphoma ) . The patient must , judgment investigator , appropriate candidate experimental therapy available standard therapy fail provide clinical benefit disease . Have presence measurable nonmeasurable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) Revised Response Criteria Malignant Lymphoma . Parts A B : measurable nonmeasurable disease . Part C : measurable disease . Have adequate organ function , include : Hematologic : Absolute neutrophil count ( ANC ) great equal 1.5 x 109/L , platelet great equal 100 x 109/L , hemoglobin great equal 8 g/dL . Transfusions allow reach 8 g/dL prior enrollment . Hepatic : Bilirubin le equal 1.5 time upper limit normal ( ULN ) , alanine aminotransaminase ( ALT ) , aspartate aminotransaminase ( AST ) less equal 2.5 time ULN . If liver tumor involvement , AST ALT equal less equal 5 time ULN acceptable . Renal : Serum creatinine less equal 1.5 time ULN calculate creatinine clearance great 45 ml/mn . Have performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have discontinue previous treatment cancer recover acute effect therapy : least 28 day myelosuppressive agent 14 day nonmyelosuppressive agent . At discretion investigator , hormonerefractory prostate cancer patient stable gonadotropinreleasing hormone ( GnRH ) agonist therapy may treatment continue enrol study . Have receive treatment within 28 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication . Have serious preexist medical condition ( leave discretion investigator ) . Have symptomatic central nervous system ( CNS ) malignancy metastasis ( screen require ) . Patients treat CNS metastasis eligible study currently receive corticosteroid and/or anticonvulsant , disease asymptomatic radiographically stable least 60 day . Have current acute chronic leukemia . Have active fungal , bacterial , and/or know viral infection include human immunodeficiency virus ( HIV ) viral ( A , B , C ) hepatitis ( screen require ) . Have second primary malignancy judgment investigator sponsor may affect interpretation result . Have QTc interval &gt; 470 msec screen electrocardiogram ( ECG ) . Treatment strong CYP3A4 substrate narrow therapeutic range , strong inhibitor , inducer . Have history pituitary adenoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>